Northwest Biotherapeutics (OTCMKTS:NWBO) Stocks Surges After Presentation of DCVax®-L

Northwest Biotherapeutics (OTCMKTS:NWBO) is up 25% after the biotech firm creating DCVax tailored immune treatment for solid tumors reported that it will make a presentation titled, “Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma” at the Frontiers of Cancer Immunotherapy Conference on May 10, 2022, at New York Academy Sciences.

Market Stats     

On Wednesday, NWBO stock soared 25% to $1.62 with more than 9.54 million shares, compared to its average volume of 1.65 million shares. The stock moved within a range of $1.2800 – 1.6400 after opening trading at $1.32.

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences

The company focuses on developing cost-effective personalized immunotherapies for cancer treatment effectively relative to existing therapies without toxicities related to chemotherapies in Europe and North America.It has a broad tech platform for DCVax dendritic cell-based vaccines.

Its lead study is a 331-patient in a third phase study evaluating DCVAx-L for recently identified Glioblastoma multiforme (GBM). Notably, GBM which is an orphan disease is the most virulent and fatal type of brain cancer. Also, the company has developed DCVax-Direct which is a product for inoperable solid cancers. So far the company has finalized a 40-patient first phase study and seeks to move forward with second phase trials if resources allow. So NWBO is worth watching.

Traders Corner

NWBO stock is trading above the 20-Day and 50-Day Moving averages of $1.04 and $0.86 respectively. Moreover, the stock is trading above the 200-Day moving average of $0.99.